1. "Sean Devlin"
  2. "Sham Mailankody"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (12)
  3. Correspondence (2)
  4. Research Letter (1)
Groups
  1. Biostatistics Service (45)
  2. Center for Hematologic Malignancies (45)
  3. Department of Medicine (45)
  4. Epidemiology and Biostatistics (45)
  5. Hematologic Malignancies Research (45)
  6. Hematologic Malignancies, Division of (45)

More Groups

People
  1. Sean Devlin (45)
  2. Sham Mailankody (45)
  3. Alexander Lesokhin (41)
  4. Hani Hassoun (38)
  5. Neha Korde (38)
  6. Sergio Giralt (38)

More People

Years
  1. 2023 (7)
  2. 2022 (4)
  3. 2021 (6)
  4. 2020 (6)
  5. 2019 (5)
  6. 2018 (5)

More Years

Publications
  1. Blood (17)
  2. Clinical Lymphoma, Myeloma and Leukemia (7)
  3. Biology of Blood and Marrow Transplantation (5)
  4. Leukemia and Lymphoma (5)
  5. Journal of Clinical Oncology (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (18)
  2. Elsevier Inc. (12)
  3. Taylor & Francis Group (5)
  4. American Society of Clinical Oncology (2)
  5. Nature Publishing Group (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Correspondence

    Shah, U. A.; Whiting, K.; Devlin, S.; Ershler, R.; Kanapuru, B.; Lee, D. J.; Tahri, S.; Gwise, T.; Rustad, E. H.; Mailankody, S.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Correspondence

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: A case for response-adapted approach
    Journal Article

    Lahoud, O. B.; Landau, H.; Nguyen, J.; Devlin, S.; Lendvai, N.; Weltz, J.; Ayorinde, T.; Chung, D. J.; Lesokhin, A. M.; Kewalramani, T.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save